 |
 |
| Home |
| Clinical Trial Search |
| Mailing List |
| Clinical Trial FAQs |
| Participation FAQs |
| Clinical Trials Glossary |
| About Informed Consent |
| Medical Research Areas |
| Clinical Trial Links |
| How to use this System |
|
This site is intended for U.S. residents only. For Novartis Worldwide, Click here |
|
|
 |
Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only. | |
|
|
|
|
|
|
|||
Clinical Trial Search
Gout
This is an acute form of arthritis that is nearly always associated with a long-lasting, abnormally high concentration of uric acid in the blood, which can lead to the deposition of urate crystals in and around joints (often those involving the big toe), producing pain, swelling, and other signs of inflammation. It mostly affects men age 40 and older.
Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial. For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy. Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.
Gout Study CACZ885H2255
The purpose of this clinical research study is to find out if the drug ACZ885 is safe and has beneficial effects in people who have acute flares in gout, a common form of inflammatory joint disease.
This study is for participants who either cannot tolerate, are contraindicated (should not take) or have experienced ineffective treatment with non-steroidal anti-inflammatory drugs (NSAIDs) and/or colchicines.
The study drug ACZ885 is considered investigational which means it is still being tested, is not yet approved by the FDA and is NOT available for sale in the U.S.
Trial phase: Phase 2 Participation Duration: Participants will be required to visit the study center 5 times over an 8 week period. Protocol Number: CACZ885H2255 |
